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Discovery of a Novel Aggregation Domain in the Huntingtin Protein:
Implications for the Mechanisms of Htt Aggregation and Toxicity**
Zhe-Ming Wang and Hilal A. Lashuel*
Huntingtons Disease (HD) is caused by CAG trinucleotide
expansion, which translates to polyQ repeats, within exon1 of
the Htt gene, which encodes for the Huntingtin (Htt),
a 350 kDa protein (Figure 1A) that is highly expressed in
the brain and different organs.[1] In HD-affected people, the
length of the polyQ repeat varies from 36–120 residues, with
a length of 42–50 residues being associated with adult onset,
and a length of over 60 residues associated with juvenile
onset.[2] Although the mechanisms by which the expanded
polyQ contribute to Htt-induced toxicity remain unknown,
the formation of nuclear inclusions of Htt in the brain of HD
patients is an invariant feature and thought to contribute to
disease pathogenesis by a gain-of-toxic-function and partial
loss of normal function linked to the polyQ mediated Htt
aggregation.[3] The toxic fragment hypothesis suggests that
proteolysis plays a crucial role in the pathogenesis of HD and
proposes that N-terminal Htt fragments (NtHtts) containing
the polyQ domain may constitute the primary toxic form of
Htt by virtue of the ability to aggregate rapidly, nucleate, and
accelerate the aggregation process.[4] The inverse correlation
between the length of the polyQ and the age at onset and
severity[5] initially led to the suggestion the polyQ is the
primary determinant of Htt aggregation and toxicity. More-
over, several studies have demonstrated a direct relationship
between the length and the aggregation propensity of polyQ
repeats in peptides,[6] NtHtts,[7] and full-length Htt (Fl-Htt)
in vitro, in cultured cells and animal models.[8] This hypothesis
was further supported by the identification of other polyQ-
containing proteins as key players in other neurodegenerative
diseases (e.g. SBMA and the SCAs).
However, several lines of evidence suggest that Htt
oligomerization, inclusion formation, and toxicity are strongly
influenced by sequences outside the polyQ domain. This
hypothesis is supported by several findings that indicate
extensive cross-talk and interactions between the different
domains in Htt: 1) Mutations, deletions, or post-translational
modifications (PTMs) within the flanking sequences of the
polyQ repeats region in Httex1 (N-terminal 17 amino acids
[Nt17],[7,10] polyP,[11] and (P/Q) repeat domains) strongly
influence the aggregation, cellular behavior, and toxicity of
mutant Htt.[9] 2) NtHtt fragments of different lengths (e.g., 67,
117, 171, and 586) containing similar numbers of polyQ
repeats exhibit different aggregation and toxicity properties
in cellular and animal models of HD.[4d,12] 3) The longer NtHtt
fragments showed enhanced aggregation (e.g. Htt1–117) and/
or toxicity (Htt1–208[13]) compared with the shorter exon1
fragment. Altogether, these findings indicate that the
sequence context is an important determinant of polyQ-
mediated Htt aggregation and toxicity.
While working on the chemical synthesis of the NtHtt
fragment comprising residues 1–140 (Figure 1A), we
observed that the residues 105–138 exhibited poor solubility
and a high propensity to form amyloid-like fibrils in vitro.
This direct observation combined with the fact that this
peptide contains sequences shared by several well-character-
ized NtHtt fragments prompted us to further investigate the
structural and biophysical properties of this peptide. To
identify the sequences that are responsible for its enhanced
aggregation properties, we generated a series of synthetic
peptide fragments spanning different region of Htt105–138
and assessed their structural and aggregation properties using
circular dichroism (CD), transmission electron microscopy
(TEM), and the Thioflavin T (ThT) fluorescence assay. Our
studies led to the discovery and identification of novel
sequences within exons2 and 3 of Htt that exhibit a high
propensity to aggregate and form amyloid-like fibrils.
To solubilize the peptides, we followed the procedure
developed by Chen and Wetzel.[14] The Htt105–138 was
subjected to this method and then prepared as a 40 mm
solution in 10 mm Tris pH 7.4 buffer. The far-UV circular
dichroism (CD) spectra obtained immediately after dissolving
the peptide in the Tris buffer showed a negative minimum
centered at approximately 220 nm and a positive maximum at
approximately 200 nm (Figure 1B). These results demon-
strate that Htt105–138 readily self-assembles to form a b-
sheet structure. TEM analysis of the same sample (Figure 1B)
revealed predominately short curvilinear structures with an
average length and diameter of 200 nm and 10 nm, respec-
tively. Interestingly, these structures do not convert with time
into the typical long filamentous structures that are character-
istic of amyloid fibrils formed by other amyloidogenic
proteins in vitro or isolated post-mortem from human
brains. To determine if the b-sheet aggregates formed by
Htt105–138 have amyloid-like characteristics, we monitored
and quantified its aggregation using the amyloid-specific dye
ThT. Figure 1B shows a time-dependent increase in ThT
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fluorescence, thereby demonstrating that the Htt105–138
aggregates bind to ThT.
To better understand the molecular and sequence deter-
minants that govern the aggregation of the Htt105–138, we
synthesized three peptides corresponding to the N-terminal
(106–116), middle (117–127), and C-terminal (128–138)
regions of Htt105–138 and assessed the propensity of each
peptide to form a b-sheet structure and to aggregate by using
CD, TEM, and ThT. Unlike Htt106–116 and Htt128–138,
Htt117–127 is readily soluble in buffers, and its CD spectrum
indicates a random coil structure. Under all incubation
conditions tested, Htt117–127 remained unstructured and
did not show any tendency to aggregate (Figure S1A Sup-
porting Information).
To examine the aggregation propensity of Htt106–116, the
peptide was prepared as a 200 mm solution in 10 mm Tris
pH 7.4 buffer after disaggregation treatment. Under these
conditions, the CD spectra showed a negative minimum
centered at approximately 195 nm and a second minimum at
218 nm consistent with a mixed structure of random coil and
b-sheet structures (Figure 1C). Upon further incubation at
37 8C, we did not observe any change in the CD spectra or
ThT signal for up to two weeks. However, after two weeks, we
observed a gradual increase in the ThT signal and a shift in the
CD spectra from a predominantly random coil to b-sheet
structure as evidenced by the negative minimum centered at
approximately 218 nm. The TEM image shown in Figure 1C
demonstrates that this peptide forms long fibrillar assemblies
with an average length and diameter of 2 mm and 11 nm,
respectively. Interestingly, at pH values under 5, especially at
pH 3.4 and 4.4, the Htt106–116 peptide (pI= 4.0) exhibited
a higher tendency to form a b-sheet-rich structure and
aggregates. Under these conditions, the CD spectra showed
a mixture of b-sheet and random coil structures with the latter
being the dominant structure. However, after 24 h, the
peptide exhibited double minima of equal intensity suggesting
an equal mixture of b-sheet and random coil structures
(Figure S1C). In contrast to Htt106–116 and Htt117–127, the
Htt128–138 peptide exhibited a very high propensity to form
b-sheet-rich fibrillar aggregates (Figure 1D). At 144 h, we
observed fibrils with an average length and diameter of
400 nm and 10 nm, respectively. The CD spectrum at time 0 is
typical for a b-sheet structure with a minimum at 218 nm and
a maximum at 195–200 nm. Upon further incubation at 37 8C
for a period of up to 6 days, the CD spectra remained
unchanged. The rapid aggregation of Htt128–138 was evident
by the high ThT signal at time 0, which remained unchanged
up to 72 h and by the detection of extensive fibrils in all
samples. These results suggest that the majority of the
Htt128–138 were already assembled into fibrils upon disso-
lution in aqueous buffer, Figure S1D.
Having identified the main regions responsible for driving
the aggregation of Htt105–138, we sought to further charac-
terize these regions and determine the key residues that
mediate the aggregation of each region. Towards this goal, we
synthesized a series of short peptides corresponding to
Figure 1. A) Schematic depiction of the Htt105–138 domain and the three peptides generated to determine the sequence determinants of its
aggregation, B,C,D) Time course aggregation of each peptide using ThT binding assay, CD, and TEM: Htt105–138 and Htt128–138 were prepared
as 40 mm solutions in 10 mm Tris pH 7.4 buffer, whereas Htt106–116 was prepared as 200 mm solutions in 10 mm Tris pH 7.4 buffer. All samples
were incubated at 37 8C; the scale bar in the TEM images represents 100 nm.
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different fragments of the two amyloid-forming sequences,
Htt106–116 and Htt128–138, and assessed the structure and
the propensity for amyloid formation of each peptide by CD,
ThT, and TEM (Figure 2). When the aggregation was assessed
at pH 7.4, only Htt105–138 and Htt128–138 showed an
increase in the ThT signal with time and formed amyloid
fibrils (Figure 2B). Interestingly, even at a higher concen-
tration (200 mm), the N-terminal-derived peptides did not
aggregate.
Consistent with the results in Figure 1C, Htt106–116
showed only a slight increase in ThT signal, and rare fibrils
were detected by TEM. However, similar to Htt106–116,
Htt108–116 (pI= 4.0) also demonstrated a pH-dependent
aggregation behavior (Figure S1E) and exhibited a higher
aggregation propensity at pH values under 5, Htt108–116
exhibited a CD spectrum that is consistent with the presence
of a predominantly b-sheet-rich structure (Figure 2C). Taken
together, these results suggest that the first four residues,
LTIC, are important for the aggregation of the Htt106–116
peptide. Similarly, the removal of the last three C-terminal
residues, LCS (Htt128–135), resulted in the significant
inhibition of b-sheet formation (Figure 2D) and abolished
the aggregation of Htt128–138, suggesting that these three
residues are essential for the aggregation of this peptide. The
aggregation of both peptides (Htt106–116 and Htt128–138)
was not influenced by the presence of reducing agent, thus
ruling out the possibility of disulfide-mediated assembly.
To further validate our findings and determine the critical
role of the N-terminal region (Htt106–116) in the aggregation
of the longer peptide Htt105–138, the following peptides were
synthesized: Htt110–138 and Htt117–138. Figure 3C illus-
trates that upon dissolution, both peptides possess a transient
helical structure but undergo rapid transformation to a b-
sheet-rich structure. Interestingly, the removal of the Htt106–
116 but not the first four amino acids (106–110) resulted in
a significant reduction of amyloid formation (Figure 3B).
Both peptides formed classical amyloid-like fibrillar struc-
tures (Figure 3D) but differed in their average length and
diameter: 2 mm and 12 nm for Htt110–138 and 830 nm and
15 nm for Htt117–138. Similarly, to determine which C-
terminal residues are critical for aggregation, we synthesized
two peptides in which either the last 3 or 11 amino acids were
removed: Htt106–135 and Htt106–127, respectively. The
removal of the C-terminal residues 128–138 resulted in
enhanced solubility and a significant reduction in the b-
sheet structure and amyloid formation (Figure 3C). Upon
dissolving the peptide in aqueous buffer, its CD spectrum
showed a minima at 200 nm and 222 nm indicating the
presence of a mixed random coil and b-sheet structure.
Consistent with this interpretation was the presence of short
fibrillar structures with an average length and diameter of
Figure 2. Identification of key amino acids that are required for the aggregation of the two amyloidogenic regions: A) Schematic depiction of the
various peptides that were made and characterized. B) Comparison of the ThT binding time course of the 9 peptides: samples were prepared as
40 mm solutions in 10 mm Tris pH 7.4 buffer except for Htt106–116 series (200 mm). C,D) CD spectra of the Htt106–116 and Htt128–138 series:
samples were prepared as 200 mm (C) and 40 mm (D) solutions in 10 mm Tris pH 7.4 buffer or 10 mm NaAc pH 4.4, and incubated at 37 8C.
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400 nm and 12 nm, respectively. The corresponding ThT
fluorescence signal is consistent with a lower propensity to
form amyloid structure compared to Htt106—135 (Fig-
ure 3B). Although the removal of the last three C-terminal
amino acids (LCS) was sufficient to abolish the aggregation of
the short peptide Htt128–138, in the context of the full-length
peptide, it reduced but did not block b-sheet and fibril
formation by Htt106–135. The fibrillar structure of Htt106–
135 has an average length and diameter of 700 nm and 13 nm,
respectively. These findings combined with the increased
aggregation properties of Htt128–138 compared with Htt106–
116 (Figure 1) or Htt108–116 (Figure 2) suggest that both of
these regions contribute to the aggregation of Htt105–138 and
NtHtts, with the Htt128–138 being more amyloidogenic. To
what extent these two amyloidogenic regions contribute to
the aggregation and toxicity of the full-length protein remains
unknown. However, given that either or both of these regions
could become highly exposed upon proteolysis of Htt, they
could potentially contribute significantly to enhancing the
aggregation properties of the NtHtt fragments.
Htt105–138 is located within the NtHtt fragments and its
residues span exon2 (Htt91–118) and exon3 (Htt119–158),
Figure 1A. Interestingly, two NtHtt fragments used to gen-
erate anima l models of HD (Htt1–117 and Htt1–171)[12a,b]
were shown to give rise to different phenotypes. For the
Htt1—117 fragment, one of the amyloidogenic regions that
we identified (106–116) is present and highly exposed,
whereas in the Htt1–171 NtHtt fragment, the entire amyloi-
dogenic domain, 105–138, is present. Based on our results, we
predict that both NtHtt fragments would exhibit increased
aggregation propensity relative to exon1 (1–90), with similar
polyQ repeats. The overexpression of an expanded variant of
Htt1–117 (“shortstop” mice) was reported to result in
significantly increased and widespread inclusions compared
with an exon1 variant containing the same polyQ repeats.
Despite this increased aggregation, the shortstop mice did not
show any signs of neurodegeneration or behavioral defi-
cits.[12a] However, these findings were recently challenged by
another study demonstrating that overexpression of Htt1–
118–82Q with a different promoter resulted in phenotypes
similar to the R6/2 and N171–82Q models. Despite the
differences in terms of pathological phenotypes, overexpres-
sion of mutant forms of Htt1–117/118 result in enhanced
aggregation or the formation of larger inclusions.[15]
Figure 3. A) Schematic depiction of the various peptides that were made to validate the relative contribution of the N- and C-terminal regions
(yellow back ground)) to the aggregation of 105–138, B) Comparison of the extent of fibril formation of the 5 peptides shown in (A) by using the
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Our findings that the peptide (LTICENIVAQS) corre-
sponding to the C-terminal residues of Htt1–117 and 1–
118(82Q) exhibits a high propensity to aggregate may explain
the increased aggregation of the shortstop protein and the
formation of larger inclusions in the transgenic mice express-
ing Htt1–118(82Q). Similarly, the expanded (82Q) Htt1–171
formed more neuronal pathology and showed greater toxicity
than the exon1 and the expanded FL–Htt.[13] This fragment
contains the entire amyloidogenic domain (105–138) and thus
would be expected to exhibit increased aggregation and
inclusion formation compared with the shorter N-terminal
fragments (exon1 and shortstop). Altogether, these findings
are consistent with increasing evidence indicating that
although the expanded polyQin Htt and other proteins
plays a central role in the pathogenesis of HD, it is not the
sole determinant of Htt aggregation and toxicity. The flanking
sequences within exon1 and the length of the NtHtt fragment
influence the proteins structure, aggregation, subcellular
localization and toxicity.
Herein, we describe for the first time the discovery of
a novel amyloidogenic domain (105–138) outside exon1 of the
Htt protein. A systematic analysis of peptides spanning
different regions within this domain led to the identification
of two distinct sequence motifs (108–116 and 128–138) that
are responsible for the aggregation of this domain. Our results
suggest that the aggregation propensity of this novel amyloi-
dogenic domain may influence the rate and aggregation
pathway of the NtHtt fragments and their toxicity to an extent
that is dependent on whether either or both amyloid-forming
motifs are present in these fragments. Given that multiple Htt
fragments, extending beyond residue 138 have been shown to
exist in vivo, conducting a similar and more expanded
systematic analysis of N-terminal residues beyond residue 138
would be interesting to determine whether these regions may
contain other amyloidogenic or protective sequences. The
interplay between these different domains may account for
the differences in aggregation, toxicity and disease pathology
exhibited by the various N-terminal Htt fragments.
Taken together, our results provide novel insight into the
possible molecular bases underlying the differences in
aggregation, toxicity and neurologic phenotypes observed
for the expanded N-terminal fragments spanning exons1–3 of
Htt in HD model systems. Further studies are required to
investigate potential cross-talk between the novel aggregation
motifs identified in this work and the polyQ repeat region and
elucidate their potential roles in regulating the physiological
and pathogenic properties of the full-length protein and
disease-associated N-terminal fragments in cell culture and
animal models of HD.
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Discovery of a Novel Aggregation
Domain in the Huntingtin Protein:
Implications for the Mechanisms of Htt
Aggregation and Toxicity
Aggravating aggregation : An N-terminal
domain that is in close proximity to the
polyQ domain in the huntingtin protein,
htt105–138 is shown to be highly aggre-
gation prone (see scheme). Potential
cross-talk between this domain and the
polyQ region may play a central role in
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